ANDA 206831, held by Eugia Pharma. Isosulfan Blue.
As of Nov 16, 2026, ANDA 206831 (Isosulfan Blue), held by Eugia Pharma, was first approved by FDA on Feb 2, 2016, with 0 approved supplements and 0 published complete response letters.
Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities. 1.1 Lymphatic Vessel Delineation Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 2, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Isosulfan Blue50MG/5ML (10MG/ML) · solution;subcutaneous | Isosulfan Blue | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters